Expression of IL-33 in the epidermis: The mechanism of induction by IL-17

Journal of Dermatological Science

Volumn 71, Issue 2, 2013, Pages 107-114

  Meephansan, Jitlada ^a,b   Komine, Mayumi ^a   Tsuda, Hidetoshi ^a   Karakawa, Masaru ^a   Tominaga, Shin ichi ^a   Ohtsuki, Mamitaro ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b THAMMASAT UNIVERSITY   (Thailand)

Author keywords

IL 17; IL 33; Normal human keratinocytes; Psoriasis; Signaling pathway

Indexed keywords

ADENOVIRUS VECTOR; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR; INTERLEUKIN 17; INTERLEUKIN 33; JANUS KINASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; STAT1 PROTEIN;

ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; CYTOPLASM; EPIDERMIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PSORIASIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

IL-17; IL-33; NORMAL HUMAN KERATINOCYTES; PSORIASIS; SIGNALING PATHWAY;

CYTOKINES; EPIDERMIS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEK293 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTERLEUKIN-17; INTERLEUKINS; KERATINOCYTES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PSORIASIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 84880331302     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2013.04.014     Document Type: Article

References (42)

1. Schmitz J., Owyang A., Oldham E., Song Y., Murphy E., McClanahan T.K., et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005, 23:479-490.
2. Moussion C., Ortega N., Girard J.P. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'?. PLoS ONE 2008, 3:e3331.
3. Smithgall M.D., Comeau M.R., Yoon B.R., Kaufman D., Armitage R., Smith D.E. IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int Immunol 2008, 20:1019-1030.
4. Liew F.Y., Pitman N.I., McInnes I.B. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol 2010, 10:103-110.
5. Smith D.E. IL-33: a tissue derived cytokine pathway involved in allergic inflammation and asthma. Clin Exp Allergy 2010, 40:200-208.
6. Hayakawa M., Hayakawa H., Matsuyama Y., Tamemoto H., Okazaki H., Tominaga S.I. Mature interleukin-33 is produced by calpain-mediated cleavage in vivo. Bichem Biophys Res Commun 2009, 387:218-222.
7. Sweet M.J., Leung B.P., Kang D., Sogaard M., Schulz K., Trajkovic V., et al. A novel pathway regulating lipopolysaccharide-induced shock by ST2/T1 via inhibition of Toll-like receptor 4 expression. J Immunol 2001, 166:6633-6639.
8. Ali S., Mohs A., Thomas M., Klare J., Ross R., Schmitz M.L., et al. The dual function cytokine IL-33 interacts with the transcription factor NF-kappaB to dampen NF-kappaB-stimulated gene transcription. J Immunol 2011, 187:1609-1616.
9. Kastelan M., Massari L.P., Pasic A., Gruber F. New trends in the immunopathogenesis of psoriasis. Acta Dermatovenerol Croat 2004, 12:26-29.
10. Teunissen M.B., Koomen C.W., de Waal M.R., Wierenga E.A., Bos J.D. Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol 1998, 111:645-649.
11. Arican O., Aral M., Sasmaz S., Ciragil P. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm 2005, 2005:273-279.
12. Albanesi C., Cavani A., Girolomoni G. IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: synergistic or antagonist effects with IFN-gamma and TNF-alpha. J Immunol 1999, 162:494-502.
13. Chiricozzi A., Guttman-Yassky E., Suarez-Farinas M., Nograles K.E., Tian S., Cardinale I., et al. Integrative responses to IL-17 and TNF-alpha in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol 2011, 131:677-687.
14. Hueber A.J., Alves-Filho J.C., Asquith D.L., Michels C., Millar N.L., Reilly J.H., et al. IL-33 induces skin inflammation with mast cell and neutrophil activation. Eur J Immunol 2011, 41:2229-2237.
15. Meephansan J., Tsuda H., Komine M., Tominaga S.I., Ohtsuki M. Regulation of IL-33 expression by IFN-gamma and tumor necrosis factor-alpha in normal human epidermal keratinocytes. J Invest Dermatol 2012, (June). 10.1038/jid.2012.185.
16. Xu D., Jiang H.R., Kewin P., Li Y., Mu R., Fraser A.R., et al. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci U S A 2008, 105:10913-10918.
17. Ruddy M.J., Wong G.C., Liu X.K., Yamamoto H., Kasayama S., Kirkwood K.L., et al. Functional cooperation between interleukin-17 and tumor necrosis factor-alpha is mediated by CCAAT/enhancer-binding protein family members. J Biol Chem 2004, 279:2559-2567.
18. Henness S., van T.E., Ge Q., Armour C.L., Hughes J.M., Ammit A.J. IL-17A acts via p38 MAPK to increase stability of TNF-alpha-induced IL-8 mRNA in human ASM. Am J Physiol Lung Cell Mol Physiol 2006, 290:L1283-L1290.
19. Lee J.W., Wang P., Kattah M.G., Youssef S., Steinman L., DeFea K., et al. Differential regulation of chemokines by IL-17 in colonic epithelial cells. J Immunol 2008, 181:6536-6545.
20. Subramaniam S.V., Cooper R.S., Adunyah S.E. Evidence for the involvement of JAK/STAT pathway in the signaling mechanism of interleukin-17. Biochem Biophys Res Commun 1999, 262:14-19.
21. Gaffen S.L. Structure and signaling in the IL-17 receptor superfamily. Nat Rev Immunol 2009, 9(8):556. 10.1038/nri2586.
22. Hot A, Lavocat F, Lenief V, Miossec P. Simvastatin inhibits the pro-inflammatory and pro-thrombotic effects of IL-17 and TNF-α on endothelial cells. Ann Rheum Dis. 2012 August 21. [Epub ahead of print].
23. Balato A., Lembo S., Mattii M., Schiattarella M., Marino R., De Paulis A., Balato N., Ayala F. IL-33 is secreted by psoriatic keratinocytes and induces pro-inflammatory cytokines via keratinocyte and mast cell activation. Exp Dermatol 2012, 21(November (11)):892-894.
24. Chustz R.T., Nagarkar D.R., Poposki J.A., Favoreto S., Avila P.C., Schleimer R.P., Kato A. Regulation and function of the IL-1 family cytokine IL-1F9 in human bronchial epithelial cells. Am J Respir Cell Mol Biol 2011 Jul, 45(1):145-153.
25. Jones C.E., Chan K. Interleukin-17 stimulates the expression of interleukin-8, growth-related oncogene-alpha, and granulocyte-colony-stimulating factor by human airway epithelial cells. Am J Respir Cell Mol Biol 2002, 26:748-753.
26. Laan M., Cui Z.H., Hoshino H., Lotvall J., Sjostrand M., Gruenert D.C., et al. Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways. J Immunol 1999, 162:2347-2352.
27. Zhu S., Qian Y. IL-17/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential. Clin Sci (Lond) 2012, 122:487-511.
28. Gaffen S.L. An overview of IL-17 function and signaling. Cytokine 2008, 43:402-407.
29. Shen F., Gaffen S.L. Structure-function relationships in the IL-17 receptor: implications for signal transduction and therapy. Cytokine 2008, 41:92-104.
30. Robinson M.J., Cobb M.H. Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 1997, 9:180-186.
31. Rahman M.S., Yamasaki A., Yang J., Shan L., Halayko A.J., Gounni A.S. IL-17A induces eotaxin-1/CC chemokine ligand 11 expression in human airway smooth muscle cells: role of MAPK (Erk1/2, JNK, and p38) pathways. J Immunol 2006, 177:4064-4071.
32. Hosokawa Y., Hosokawa I., Ozaki K., Nakae H., Matsuo T. Interleukin (IL)-17A synergistically enhances CC chemokine ligand 20 production in IL-1beta-stimulated human gingival fibroblasts. Hum Immunol 2012, 73:26-30.
33. Andoh A., Shimada M., Bamba S., Okuno T., Araki Y., Fujiyama Y., et al. Extracellular signal-regulated kinases 1 and 2 participate in interleukin-17 plus tumor necrosis factor-alpha-induced stabilization of interleukin-6 mRNA in human pancreatic myofibroblasts. Biochim Biophys Acta 2002, 1591:69-74.
34. Inoue D., Numasaki M., Watanabe M., Kubo H., Sasaki T., Yasuda H., et al. IL-17A promotes the growth of airway epithelial cells through ERK-dependent signaling pathway. Biochem Biophys Res Commun 2006, 347:852-858.
35. Kanda N., Shibata S., Tada Y., Nashiro K., Tamaki K., Watanabe S. Prolactin enhances basal and IL-17-induced CCL20 production by human keratinocytes. Eur J Immunol 2009, 39:996-1006.
36. Lee J.W., Wang P., Kattah M.G., Youssef S., Steinman L., DeFea K., et al. Differential regulation of chemokines by IL-17 in colonic epithelial cells. J Immunol 2008, 181:6536-6545.
37. Wang Q., Li H., Yao Y., Xia D., Zhou J. The overexpression of heparin-binding epidermal growth factor is responsible for Th17-induced airway remodeling in an experimental asthma model. J Immunol 2010, 185:834-841.
38. Mascia F., Mariani V., Girolomoni G., Pastore S. Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am J Pathol 2003, 163:303-312.
39. Huang F., Kao C.Y., Wachi S., Thai P., Ryu J., Wu R. Requirement for both JAK-mediated PI3K signaling and ACT1/TRAF6/TAK1-dependent NF-kappaB activation by IL-17A in enhancing cytokine expression in human airway epithelial cells. J Immunol 2007, 179:6504-6513.
40. Saleh A., Shan L., Halayko A.J., Kung S., Gounni A.S. Critical role for STAT3 in IL-17A-mediated CCL11 expression in human airway smooth muscle cells. J Immunol 2009, 182:3357-3365.
41. Shi X., Jin L., Dang E., Chang T., Feng Z., Liu Y., et al. IL-17A upregulates keratin 17 expression in keratinocytes through S. J Invest Dermatol 2011, 131:2401-2408.
42. Leigh I.M., Pulford K.A., Ramaekers F.C., Lane E.B. Psoriasis: maintenance of an intact monolayer basal cell differentiation compartment in spite of hyperproliferation. Br J Dermatol 1985, 113:53-64.